Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X<sub>L</sub> cell survival genes.
|
29357840 |
2018 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Bcl-2 mediated modulation of vascularization in prostate cancer xenografts.
|
19107861 |
2009 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We have previously demonstrated that prostate tumors that highly express Bcl-2 are not only more tumorigenic, but also more angiogenic than low Bcl-2 expressing tumors.
|
19495772 |
2009 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate.
|
18573594 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
|
17917084 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The mRNA and protein levels of Bcl-2 are significantly increased in androgen-independent prostate cancer cells. shRNA-mediated gene silencing of Bcl-2 in androgen-independent prostate cancer cells promotes UV-induced apoptosis and suppresses the growth of prostate tumors in vivo.
|
17404601 |
2007 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Germline BCL-2 sequence variants and inherited predisposition to prostate cancer.
|
16733517 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Germline BCL-2 sequence variants and inherited predisposition to prostate cancer.
|
16733517 |
2006 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Bcl-2 is anti-apoptotic and overexpression is associated with prostate tumor aggressiveness.
|
16015611 |
2005 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The oncogene Bcl-2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease.
|
14676836 |
2004 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
|
12629413 |
2003 |
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
|
11839683 |
2002 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells.
|
12086875 |
2002 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Three human prostate tumor cell lines (PC3, DU145 and LNCaP) and their bcl-2-expressing counterparts were tested for their susceptibility to TRAIL.
|
11439339 |
2001 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents.
|
11776759 |
2001 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We recently reported that antisense Bcl-2 oligodeoxynucleotides (ODNs) delay progression to androgen independence in the androgen-dependent (AD) human LNCaP prostate tumor model.
|
11275990 |
2001 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We examined 62 archival samples of prostate tumours from Asians of non-Japanese origin for the over-expression of p53, for the possible presence of mutated ras genes, for the overexpression of the bcl-2 and bax proteins, as well as directly for the presence of apoptotic cells by the TUNEL methodology.
|
10952781 |
2000 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Apoptotic status in prostate tumors was evaluated in situ, using the transferase deoxyuridine end labeling (TUNEL) assay, and the expression profile of two apoptotic proteins, bcl-2 and bax.
|
10617870 |
2000 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Because hormone-resistant tumors demonstrate greater expression of bcl-2 and because transfection of the bcl-2 gene into hormone-sensitive tumor cells confers resistance to both hormone therapy and chemotherapy, efforts to abrogate bcl-2 in prostate tumors represent one approach to improve clinical results.
|
10604265 |
1999 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The inverse correlation between Par-4 and Bcl-2 expression was recapitulated in human prostate tumors.
|
9989812 |
1999 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
|
10537358 |
1999 |